NOPE If the trial was heading for failure the FDA would not let the trial continue. The trial although complete is still actively recruiting but the big change is the FDA required the plecebo to be stopped and Leronlimab administered to ALL patients. This is after the FDA had access to CD12 data. The FDA will not allow a drug to continue if they had knowledge it failed.